HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma

References

• LamJSLeppertJTBelldegrunASFiglinRANovel approaches in the therapy of metastatic renal cell carcinomaWorld J Urol200523320221215812574
   PubMed Web of Science ®Google Scholar
• JanzenNKKimHLFiglinRABelldegrunASSurveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent diseaseUrol Clin North Am200330484385214680319
   PubMed Web of Science ®Google Scholar
• HsiehJJChenDWangPIGenomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinomaEur Urol201771340541427751729
   PubMed Web of Science ®Google Scholar
• FunakoshiTLeeCHHsiehJJA systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinomaCancer Treat Rev201440453354724398141
   PubMed Web of Science ®Google Scholar
• HoTHChoueiriTKWangKKaramJAChalmersZCorrelation between molecular subclassifications of clear cell renal cell carcinoma and targeted therapy responseEur J Focus201622204209
   PubMedGoogle Scholar
• DornbuschJZacharisAMeinhardtMAnalyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinomaPLoS One201389e7638624086736
   PubMed Web of Science ®Google Scholar
• HsiehJJPurdueMPSignorettiSRenal cell carcinomaNat Rev Dis Primers201731700928276433
   PubMed Web of Science ®Google Scholar
• YoungACCravenRACohenDAnalysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinomaClin Cancer Res200915247582759219996202
   PubMed Web of Science ®Google Scholar
• NickersonMLJaegerEShiYImproved identification of von Hippel-Lindau gene alterations in clear cell renal tumorsClin Cancer Res200814154726473418676741
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive molecular characterization of clear cell renal cell carcinomaNature20134997456434923792563
   PubMed Web of Science ®Google Scholar
• KimWYKaelinWGRole of VHL gene mutation in human cancerJ Clin Oncol200422244991500415611513
   PubMed Web of Science ®Google Scholar
• GordanJDThompsonCBSimonMCHIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferationCancer Cell200712210811317692803
   PubMed Web of Science ®Google Scholar
• GordanJDLalPDondetiVRHIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinomaCancer Cell200814643544619061835
   PubMed Web of Science ®Google Scholar
• GordanJDBertoutJAHuCJDiehlJASimonMCHIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activityCancer Cell200711433534717418410
   PubMed Web of Science ®Google Scholar
• KeithBJohnsonRSSimonMCHIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progressionNat Rev Cancer2012121922
   Web of Science ®Google Scholar
• BrannonARRathmellWKRenal cell carcinoma: where will the state-of-the-art lead us?Curr Oncol Rep201012319320120425079
   PubMedGoogle Scholar
• DondetiVRWubbenhorstBLalPIntegrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targetsCancer Res201272111212122094876
   PubMedGoogle Scholar
• AbramsTJLeeLBMurrayLJPryerNKCherringtonJMSU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancerMol Cancer Ther20032547147812748309
   PubMed Web of Science ®Google Scholar
• MendelDBLairdADXinXIn vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationshipClin Cancer Res20039132733712538485
   PubMed Web of Science ®Google Scholar
• O’FarrellAMAbramsTJYuenHASU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivoBlood200310193597360512531805
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBARussoPMazumdarMInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol200220128929611773181
   PubMed Web of Science ®Google Scholar
• TangSWChangWHSuYCMYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cellsCancer Lett20092731354318809243
   PubMedGoogle Scholar
• DrabkinHABradleyCHartIBleskanJLiFPPattersonDTranslo-cation of c-myc in the hereditary renal cell carcinoma associated with a t(3;8)(p14.2;q24.13) chromosomal translocationProc Natl Acad Sci U S A19858220698069842995998
   PubMedGoogle Scholar
• ShroffEHEberlinLSDangVMMYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolismProc Natl Acad Sci U S A2015112216539654425964345
   PubMed Web of Science ®Google Scholar
• VindrieuxDDevaillyGAugertARepression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growthOncotarget2014541004101324657971
   PubMedGoogle Scholar
• ShroffEHEberlinLSDangVMMYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolismProc Natl Acad Sci U S A2015112216539654425964345
   PubMed Web of Science ®Google Scholar
• PatelPHChadalavadaRSIshillNMHypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC) [presented at 2008 ASCO Annual Meeting]J Clin Oncol200826Suppl abstract 5008252s
   Google Scholar
• SaezMIPerezJMTPerez-RivasLGPerez-villaLVillatoroRMontesaAHypoxia-inducible factor (HIF) 1a and 2a as predictive markers of outcome to VEGFR tyrosine kinase inhibitors (TKI) in renal cell carcinoma (RCC)J Clin Oncol201230Suppl abstract 4630309s
   Google Scholar
• Garcia-DonasJLeandro-GarciaLJGonzalez DelAAProspective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinomaAnn Oncol20132492409241423788753
   PubMed Web of Science ®Google Scholar
• ChoueiriTKFayAPGagnonRThe role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinomaClin Cancer Res201319185218522623881929
   PubMed Web of Science ®Google Scholar
• GerlingerMRowanAJHorswellSIntratumor heterogeneity and branched evolution revealed by multiregion sequencingN Engl J Med20123661088389222397650
   PubMed Web of Science ®Google Scholar